Odyssean LLC Buys 39,495 Shares of Vera Therapeutics, Inc. $VERA

Odyssean LLC grew its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 192.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 60,005 shares of the company’s stock after buying an additional 39,495 shares during the quarter. Odyssean LLC’s holdings in Vera Therapeutics were worth $2,575,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in VERA. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the 4th quarter valued at about $46,000. Aster Capital Management DIFC Ltd acquired a new stake in Vera Therapeutics in the 4th quarter worth approximately $71,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the 2nd quarter worth approximately $51,000. Nykredit A S acquired a new stake in Vera Therapeutics in the 2nd quarter worth approximately $97,000. Finally, Sandia Investment Management LP bought a new stake in Vera Therapeutics during the fourth quarter worth approximately $127,000. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $35.28 on Wednesday. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -6.02 and a beta of 0.92. The business has a 50 day moving average price of $36.34 and a 200 day moving average price of $37.86. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics, Inc. has a twelve month low of $21.15 and a twelve month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the company earned ($1.20) earnings per share. Research analysts predict that Vera Therapeutics, Inc. will post -6.43 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on VERA shares. Wedbush reiterated a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a report on Monday, August 17th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. Finally, Evercore set a $91.00 target price on shares of Vera Therapeutics in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $81.15.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.